Scipher Medicine
Scipher Medicine is driving the probability of success at each stage of drug development from discovery to commercialization by leveraging AI with network biology, and proprietary data, through our SPECTRA Rx and Dx platforms. Scipher has the industry's largest non-oncology clinico-genomic data asset and biobank in addition to EMR data for over 3 million rheumatology patients.Content by Scipher Medicine
| 2 min read
Collaboration combines Scipher’s unique RNAseq data with InnoSIGN’s proprietary comprehensive pathway analysis (CPA) platform to enhance the understanding of complex immune-mediated diseases.
Page 1 of 1 - 1 Total Items
Subscribe to our eNewsletters
Stay connected with all of the latest from Drug Discovery News.
SubscribeSponsored
Reliable fluid biomarkers strategies for clinical neuroscience research
Explore how validated fluid biomarker assays advance clinical research for neurological diseases.
Understanding drug impurities: types, sources, and analytical strategies
Unseen and often unexpected, drug impurities can slip in at every drug development stage, making their detection and control essential.
Discovering cutting-edge nitrosamine analysis in pharmaceuticals
New tools help researchers detect and manage harmful nitrosamine impurities in drugs such as monoclonal antibodies.
